Malladi et al. discovered that Latency Competent Cancer (LCC) in lung and breast cancer, which expresses high levels of SOX2 and SOX9, undergoes autocrine Wnt/β-catenin inhibition through DKK1. This evidence concerns the gene SOX9 and breast carcinoma.